Patient Study Brochures

NRG Oncology has created study brochures (linked below) specific to certain NRG Oncology studies that are open to patient enrollment. These pages include overview information on the specific study and frequently asked questions associated with the study. Please print these brochures for you and your doctor’s consideration when discussing your treatment.

Always Speak to Your Provider Regarding Decisions Pertaining to Your Healthcare
Please note that the goal of these materials is to educate and inform about NRG Oncology trials. The information available on our website is not a substitute for medical advice. Your healthcare team is the best source for information about your treatment options, including cancer clinical trials. Please take any information you collect to your doctor to discuss your questions and concerns.


Study Brochures

Brain Tumors

NRG-BN003Can Radiation Therapy Following Surgery Improve Outcomes for Grade II Meningioma? (NCT03180268)

NRG-BN005: Could Proton Therapy Benefit Patients with Brain Tumors? (NCT03180502)

NRG-BN007Can Immune Therapy Help Extend the Life of People with a Glioblastoma (Brain Tumor)? (NCT04396860)

NRG-BN009Can Adding Whole Brain Radiation Therapy that Avoids the Hippocampus to Stereotactic Radiosurgery Extend the Life and Improve Outcomes for People with Brain Cancer that has Spread After Previous Treatment with Stereotactic Radiosurgery (NCT04588246)

Gastrointestinal Cancer

NRG-GI003Could Proton Therapy Benefit Patients with Liver Cancer? (NCT03186898)

NRG-GI004: The COMMIT Study: Comparing the Addition of the Drug Atezolizumab to the Usual Treatment Approach for Colorectal Cancer (NCT02997228)

NRG-GI005: The COBRA Study: Using Cancer DNA in the Blood to Predict if Chemotherapy will Benefit Patients who have had Surgery for Early Stage Colon Cancer (Please note: this study is temporarily suspended to accrual in the US only; it remains open in Canada.) (NCT04068103)

NRG-GI006Comparing Proton to Photon Radiation Therapy for Esophageal Cancer (NCT03801876)

Genitourinary Cancer

NRG-GU005: Stereotactic Body Radiotherapy and Prostate Cancer (NCT03367702)

NRG-GU007: A New Anti-Cancer Drug Called Niraparib in Patients with Prostate Cancer (NCT04037254)

NRG-GU008: Does Adding Two New Drugs to Usual Therapy after Radical Prostatectomy Delay the Spread of Prostate Cancer? (NCT04134260)

NRG-GU009: Testing Hormone Therapy Treatments to Improve Outcomes for Men with High-Risk Prostate Cancer Categorized by Low or High Gene Risk Score (NCT04513717)

Head and Neck Cancer

NRG-HN001: Evaluating Individualized Treatment for Nasopharyngeal Cancer Based on the Patient's DNA (NCT02135042)

NRG-HN004Comparing Radiation Plus Durvalumab to Radiation Plus Cetuximab in People with Advanced Head and Neck Cancer Who Cannot Take Cisplatin (NCT03258554)

NRG-HN006: Does Sentinel Lymph Node Biopsy Improve Survival Outcomes When Compared to Elective Neck Dissection for Early Stage Oral Cavity Cancer? (NCT04333537)

NRG-HN007Will Adding an Immune Therapy Drug to Standard Chemotherapy Extend the Life of Patients with Nasopharyngeal Cancer? (NCT04458909)

NRG-RTOG 1216 (Part 2): Is Radiation with Docetaxel and Cetuximab or Radiation with Cisplatin and Atezolizumab Better than Usual Therapy for High-Risk Head and Neck Cancer? (NCT01810913)

Lung Cancer

NRG-LU004: Evaluating the Safety of Durvalumab when Added to Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer (NCT03801902)

NRG-LU005: Chemoradiotherapy with or without the Immunotherapy Drug Atezolizumab in People with Limited-Stage Small Cell Lung Cancer (NCT03811002)

NRG-LU007: Can Adding Radiation to Immune Therapy Help Improve Survival for People with Extensive Stage Small Cell Lung Cancer? (NCT04402788)

NRG-RTOG 1308: Comparing Photon Therapy to Proton Therapy to Treat Patients with Lung Cancer (NCT01993810)

NCORP 

NRG-CC007CD: Survivorship Care Planning for Prostate Cancer (NCT03860961)

NRG-CC008: A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (NCT04251052)

 

Stay current with science. Sign up for our newsletter.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.